Education
About Us
Working with TipRanks
Follow Us
Revance Therapeutics (RVNC)
NASDAQ:RVNC
RVNC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.30 - $7.56
Previous CloseN/A
Volume1.24M
Average Volume (3M)3.08M
Market Cap
$381.02M
Enterprise Value$839.77M
Total Cash (Recent Filing)$73.26M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Mar 04, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding104,389,885
10 Day Avg. Volume3,063,872
30 Day Avg. Volume3,079,564
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.55
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market Cap2.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.26
Enterprise Value/Ebitda-5.59
Forecast
1Y Price Target
$3.05Price Target Upside-16.44% Downside
Rating ConsensusHold
Number of Analyst Covering3
---
Revance Therapeutics News
PremiumPre-Earnings
Is RVNC a Buy, Before Earnings?
PremiumCompany Announcements
Revance Therapeutics Finalizes Merger with Crown Laboratories
---
Bulls Say, Bears Say
Bulls Say
AcquisitionCrown raised its offer price for Revance from $3.10 to $3.65, indicating strong interest in acquiring the company.
Financial PerformanceRevance recorded a total revenue of $59.9M, an increase of 10.7% YoY from $54.1M in 3Q23.
Product AdoptionRevance suggests a strong 4Q24, making great progress on driving deeper adoption of Daxxify and the RHA filler line.
Bears Say
Financial PerformanceRevance withdrew 2024 product sales guidance of at least $280M following lower-than-expected results.
Market UncertaintyCrown Labs amended its offer to a lower price of $3.10/share, which some believe undervalues Revance.
Merger ChallengesCrown would need the tender of at least a majority of RVNC outstanding shares to proceed with the merger, indicating a potential challenge.
---
Ownership Overview
2.01% Insiders
31.90% Mutual Funds
0.46% Other Institutional Investors
55.79% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RVNC FAQ
What was Revance Therapeutics’s price range in the past 12 months?
Revance Therapeutics lowest stock price was $2.30 and its highest was $7.56 in the past 12 months.
What is Revance Therapeutics’s market cap?
Revance Therapeutics’s market cap is $381.02M.
When is Revance Therapeutics’s upcoming earnings report date?
Revance Therapeutics’s upcoming earnings report date is Mar 04, 2025 which is 9 days ago.
How were Revance Therapeutics’s earnings last quarter?
Revance Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.269 by -$0.101.
Is Revance Therapeutics overvalued?
According to Wall Street analysts Revance Therapeutics’s price is currently Overvalued.
Does Revance Therapeutics pay dividends?
Revance Therapeutics does not currently pay dividends.
What is Revance Therapeutics’s EPS estimate?
Revance Therapeutics’s EPS estimate is -0.26.
How many shares outstanding does Revance Therapeutics have?
Revance Therapeutics has 104,389,885 shares outstanding.
What happened to Revance Therapeutics’s price movement after its last earnings report?
Revance Therapeutics reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.269. Following the earnings report the stock price went down -35.986%.
Which hedge fund is a major shareholder of Revance Therapeutics?
Among the largest hedge funds holding Revance Therapeutics’s share is Woodline Partners LP. It holds Revance Therapeutics’s shares valued at 4M.
---
Revance Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.05 (-16.44% Downside)
$3.05 (-16.44% Downside)
Blogger Sentiment
Bullish
RVNC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 426.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $16.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.07%
12-Months-Change
Fundamentals
Return on Equity
111.29%
Trailing 12-Months
Asset Growth
-13.32%
Trailing 12-Months
Company Description
Revance Therapeutics
Revance Therapeutics, Inc. (RVNC) is a biotechnology company focused on developing and commercializing innovative aesthetic and therapeutic offerings. The company's core product is DaxibotulinumtoxinA injection, a botulinum toxin product aimed at treating facial wrinkles and other medical conditions. Revance operates primarily in the healthcare and biotechnology sectors, providing both aesthetic and therapeutic solutions to healthcare professionals and patients.
---
RVNC Stock 12 Month Forecast
Average Price Target
$3.05
▼(-16.44% Downside)
Technical Analysis
Best Analysts Covering RVNC
1 Year
---